| Etanercept | Infliximab | Adalimumab | Golimumab | Tocilizumab | Rituximab | Tofacitinib | Abatacept | Pinteraction |
---|---|---|---|---|---|---|---|---|---|
Sex | Â | Â | Â | Â | Â | Â | Â | Â | 0.783 |
 Men | 1.79 (0.95–3.37) | 1.72 (0.85–3.47) | 2.13 (1.14–3.99)* | 1.52 (0.72–3.25) | 1.16 (0.56–2.41) | 1.26 (0.16–9.90) | 2.51 (0.81–7.83) | Reference |  |
 Women | 1.09 (0.84–1.41) | 1.26 (0.97–1.66) | 1.15 (0.89–1.48) | 0.97 (0.71–1.33) | 0.84 (0.62–1.13) | 1.17 (0.56–2.44) | 2.41 (1.52–3.81)*** | Reference |  |
Age, years | Â | Â | Â | Â | Â | Â | Â | Â | 0.163 |
 ≥65 | 1.39 (0.90–2.16) | 1.21 (0.74–1.99) | 1.43 (0.91–2.24) | 1.12 (0.65–1.94) | 1.06 (0.65–1.73) | 0.48 (0.06–3.64) | 3.82 (1.92–7.59)*** | Reference |  |
 <65 | 1.13 (0.85–1.51) | 1.36 (1.01–1.83)* | 1.21 (0.92–1.59) | 1.00 (0.71–1.42) | 0.79 (0.57–1.10) | 1.35 (0.64–2.84) | 1.93 (1.12–3.34)* | Reference |  |
No. of csDMARD | Â | Â | Â | Â | Â | Â | Â | Â | 0.993 |
 ≤2 | 1.23 (0.90–1.68) | 1.38 (0.98–1.94) | 1.34 (0.98–1.83) | 1.24 (0.85–1.79) | 0.93 (0.65–1.32) | 1.48 (0.66–3.30) | 2.45 (1.44–4.17)** | Reference |  |
 >2 | 1.13 (0.79–1.63) | 1.34 (0.92–1.95) | 1.23 (0.86–1.75) | 0.83 (0.52–1.34) | 0.82 (0.53–1.29) | 0.84 (0.20–3.49) | 2.39 (1.16–4.94)* | Reference |  |
CCI | Â | Â | Â | Â | Â | Â | Â | Â | 0.649 |
 ≤2 | 0.77 (0.51–1.16) | 1.00 (0.65–1.53) | 0.90 (0.60–1.35) | 0.77 (0.47–1.26) | 0.64 (0.39–1.04) | 0.73 (0.22–2.42) | 1.52 (0.65–3.54) | Reference |  |
 >2 | 1.43 (1.07–1.91)* | 1.48 (1.08–2.03)* | 1.46 (1.10–1.96)* | 1.17 (0.82–1.67) | 0.99 (0.71–1.38) | 1.48 (0.63–3.45) | 2.86 (1.75–4.69)*** | Reference |  |
Steroidsa | Â | Â | Â | Â | Â | Â | Â | Â | 0.132 |
 ≥5 mg/day | 1.20 (0.85–1.68) | 1.52 (1.05–2.20)* | 1.43 (1.02–1.99)* | 1.07 (0.69–1.65) | 1.01 (0.68–1.51) | 2.50 (1.05–5.95)* | 1.92 (1.03–3.59)* | Reference |  |
 <5 mg/day | 1.18 (0.84–1.64) | 1.22 (0.87–1.73) | 1.16 (0.83–1.62) | 1.03 (0.70–1.53) | 0.78 (0.53–1.14) | 0.57 (0.18–1.86) | 3.24 (1.80–5.83)*** | Reference |  |